Breast			
post neoadjuvant/adjuvant breast cancer (stage I,II, III)	GLSI-100/Placebo Sub-Q injection once Monthly x 6months	**Greenwich GSLI-100 (Flamingo): Inclusion Criteria: Stage I, II, III HER2 +** breast cancer with residual disease or High-risk PCR following Neoadjuvant taxane-based chemotherapy in combination with Trastuzumab or biosimiliar), followed by surgery, postoperative Adjuvant Trastuzumab based therapy (6 cycles), known HLA-A*02 status Central testing required, must start IP within 90days of adjuvant Trastuzmab-based therapy **Exclusion Criteria:** Stage IV or metastatic BC, Inflammatory B/C	Phase III UCLA/TRIO PI: RP SC: Maria
2nd line ER/+Her- Advanced Breast cancer	ARV-471 vs Fulvestrant	**Pfizer C4891001**: **Inclusion Criteria**: ER+ Her2- advance BC, no more then 1 line of CDK4/6 inhibitor therapy in combination w ET therapy, must have at least 6months of ET prior to PD, Measurable disease, ECOG 0-1, neo/adjuvant tx is counted a 1 line of therpay if recurrence/relapse occurs within 12months of last dose	Phase III UCLA/TRIO PI: RP SC: Maria
Lung			
non-squamous NSCLC EGRF + Stage IIIB/IIIC or Metastatic Stage IV	AK112(SMT112) w pemetrexed & Carboplatin vs placebo w pemetrexed & Carboplatin	**Summit AK112-301**: **Inclusion Criteria:** Patients with non-squamous NSCLC w EGFR mutation who have disease progression following tx w 1st /2nd Gen EGFR-TKI. Measureable disease ECOG 0-1. **Exlcusion Criteria :** No CNS mets., No presence of small cell carcinoma component squamous cell carcinoma. No prior tx with immunotherapy including immune checkpoint inhibitors, agonist. No prior chemotherapies in metastatic NSCLC or EGFR inhibitor therapy, no active autoimmune diseases.	Phase III UCLA/TRIO PI: RP SC: Maria
Colorectal			
1st line Colorectal Cancer with KRAS/NRAS Mutation	open-label, Ovansertib w FOLFIRI /FOLFOX w Bevacizumab vs FLOFIRI/FOLFOX w Bevacizumab	**Pfizer Z0101001/CRDF004: Inclusion Criteria:**1st line Colorectal; no prior tx in metastatic setting. Must have KRAS/NRAS mutation status. Archival tissue or fresh biopsy for central KRAS/NRAS testing, local testing can be completed. ECOG 0-1 Measurable disease per Recist 1.1 **Exclusion Criteria:** No prior oxaliplatin treatment within 12 months prior to randomization. No BRAF V600 mutation	Phase II UCLA/TRIO PI: RP SC: Maria